Form 4: Ventyx Biosciences Director Sheila Gujrathi Granted 40,000 Stock Options

Ventyx Biosciences, Inc. Director Sheila Gujrathi was granted 40,000 stock options with an exercise price of $2.25, aligning her interests with shareholder value.

Summary

• Sheila Gujrathi, a Director of Ventyx Biosciences, Inc. (VTYX), was granted 40,000 stock options.
• The options have an exercise price of $2.25 per share.
• The transaction date for this grant was June 5, 2025.
• The options are exercisable immediately upon grant and expire on June 5, 2035.
• Vesting conditions state that the shares subject to the option will vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the day prior to the next Annual Meeting of the Issuer's stockholders, in each case, subject to continued service as a Service Provider.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning interests and is a routine, expected event in corporate compensation, indicating stability rather than significant new news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• The options are granted under the Issuer's 2021 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Risks

• The value of the stock options is dependent on the future performance of Ventyx Biosciences' stock price; if the stock price does not exceed the exercise price, the options may not hold value.
• Vesting is subject to continued service, meaning the director must remain a Service Provider for the options to fully vest.

Future Outlook

The vesting schedule for the granted options, tied to continued service, indicates an expectation for the director's ongoing involvement and contribution to Ventyx Biosciences for at least the next year or until the next annual meeting.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, align interests with shareholders, and incentivize long-term strategic decision-making. This practice is part of standard corporate governance and compensation structures.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Ventyx Biosciences.
• The exercise price of $2.25, being relatively low, is typical for options granted as compensation, often set at the market price on the grant date to provide future upside potential.
• The vesting schedule (one-year anniversary or prior to next annual meeting) is also a common approach to ensure continued commitment from directors. For example, similar vesting schedules are observed in companies like Moderna (MRNA) or Pfizer (PFE) for their non-employee directors, though specific terms vary based on company-specific compensation philosophies and plans.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value. However, it also represents potential future dilution if options are exercised.

Next Steps

• The stock options will vest according to the specified schedule (earlier of one-year anniversary of grant or day prior to next Annual Meeting), subject to Sheila Gujrathi's continued service.
• Sheila Gujrathi may choose to exercise the vested options at the exercise price of $2.25 per share at any time before the expiration date of June 5, 2035.

Key Dates

Keywords

Ventyx Biosciences, VTYX, Form 4, Stock Option, Director Compensation, Insider Transaction, Equity Incentive Plan, Sheila Gujrathi